Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
about
On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles.Transient enhancement and spectral narrowing of the photothermal effect of plasmonic nanoparticles under pulsed excitation.EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complexEGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalkImmune biomarkers of anti-EGFR monoclonal antibody therapyMammalian target of rapamycin and head and neck squamous cell carcinomaResults of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.Rapid detection and destruction of squamous cell carcinoma of the head and neck by nano-quadrapeutics.Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assaysPET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model.Intraoperative diagnostics and elimination of residual microtumours with plasmonic nanobubbles.Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancerOptical molecular imaging of multiple biomarkers of epithelial neoplasia: epidermal growth factor receptor expression and metabolic activity in oral mucosa.Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancerBalancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft modelThe molecular pathogenesis of head and neck squamous cell carcinomaInactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6.STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.The Role of p53 and MDM2 in Head and Neck Cancer.Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.The clinical implications of antitumor immunity in head and neck cancer.Targeted therapy in head and neck cancer.Cetuximab in non-melanoma skin cancer.Head and neck cancer: from anatomy to biology.Hazards and risks in oncology: radiation oncology.Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks.Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines.ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line.RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.
P2860
Q30407976-DB36D865-0027-4340-8BC2-7C2FF776A9FDQ30414855-4426D6F5-77A3-4C89-A3A3-D61ACD30A0BAQ30835988-7D29789F-2F19-42FF-AB84-BC8E9881073DQ34117589-B685997D-0162-4FF2-8EF7-36A1D8A8D325Q34194706-86F9612F-DF85-4515-83AE-8532E3C830D2Q34498746-ECF51BFE-0328-4E66-8D05-8E1A970DC988Q34654728-B4D8FA5B-E7E2-4AC6-B288-14DAAA1466EDQ34723594-36DE8926-5D1A-429A-BE4B-16F21D07C4F7Q35027222-F902708B-CE1A-4632-B98F-44AF3E25226DQ35223807-5201A5CB-0750-4994-AC54-6F1C8343CBF1Q35560212-3E286750-842E-4447-A508-0911E3A34B75Q35631966-2D390EA1-0B83-403A-B186-9294D2E1905AQ35683116-45B6154B-EB69-4509-9049-D80A333E665AQ35924002-A71CEE09-562C-48A9-9162-6C07B8D4FF9BQ35986801-D11144C5-659B-4D07-BB47-25DE7BDCABAFQ36005545-1D88F057-FC43-4150-B402-F6953F23F7ADQ36061785-E5CCE4AB-FBA2-4D07-92C2-1628949A7F52Q36109779-A6606302-1965-4AC8-A465-85920C0EB7B8Q36371601-90CCF63D-4CD5-4908-912E-486E0B046BCEQ36642153-148F5538-BA92-40DB-9429-831C9DB5E64EQ36659339-03AB467F-52F6-4604-86CF-090C04789CB4Q36675764-DF3356D6-ACEF-4C9E-BF78-4619E525900CQ36733391-24EA3CE0-61BF-4939-85A7-943CDFD0BCD4Q36857374-9791D4C9-0E2F-47FD-8D37-A0474C01D1ABQ37218978-16DB1B8F-92F6-4E65-BC9B-A13F2464442BQ37362560-547653A1-320D-4279-9C88-5E303F5D6A02Q37589257-BC22D1B5-F419-4F2C-98C0-95436B4E386DQ37633071-E22D0A11-0CE4-49C8-A04A-E5A8753E42E3Q37712686-7E772D46-26C0-40C2-8F2F-D78F4F4AF408Q37895956-98AB17AD-41F2-4DC7-AA06-A9F475FCF5E7Q37970005-EFA71ACB-719E-48D8-A631-BFD412961733Q37988981-74B12EC5-3746-42D9-AB2B-0B5ED89BCA28Q38004033-042AF9A2-6D3C-448C-8148-801DCAC7C1F2Q38082457-07A5E703-AC77-415A-ACD9-FBDF26228ECAQ38176904-A3DD000D-7ED7-4A8A-BD9A-A6E33E3AB2F9Q38291542-6DA275C7-1902-4B6F-B94C-558487A54C8FQ38572591-90C3F53A-2F46-4078-AAD4-B1143D3C6D9CQ38607113-18EB6F0E-0D6E-456B-91DE-B1B326148117Q38720608-A27EFDB4-DFE4-424B-8811-D851564E279CQ38916329-F5769EB1-B575-4078-BFA5-D638701EB185
P2860
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Epidermal growth factor recept ...... carcinoma of the head and neck
@ast
Epidermal growth factor recept ...... carcinoma of the head and neck
@en
Epidermal growth factor recept ...... carcinoma of the head and neck
@nl
type
label
Epidermal growth factor recept ...... carcinoma of the head and neck
@ast
Epidermal growth factor recept ...... carcinoma of the head and neck
@en
Epidermal growth factor recept ...... carcinoma of the head and neck
@nl
prefLabel
Epidermal growth factor recept ...... carcinoma of the head and neck
@ast
Epidermal growth factor recept ...... carcinoma of the head and neck
@en
Epidermal growth factor recept ...... carcinoma of the head and neck
@nl
P2860
P356
P1433
P1476
Epidermal growth factor recept ...... carcinoma of the head and neck
@en
P2093
Mark E Sharafinski
Soldano Ferrone
P2860
P304
P356
10.1002/HED.21365
P577
2010-10-01T00:00:00Z